# Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

> **NCT00115739** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00115739
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2008-05
- **Final completion:** 2010-08
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study was closed early due to slow accrual
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115739, "Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00115739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*